The spectrum of growth hormone excess in Carney complex and genotype-phenotype correlations.

Carney complex acromegaly growth hormone pituitary

Journal

The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362

Informations de publication

Date de publication:
13 Apr 2024
Historique:
received: 31 08 2023
revised: 06 04 2024
accepted: 10 04 2024
medline: 16 4 2024
pubmed: 16 4 2024
entrez: 16 4 2024
Statut: aheadofprint

Résumé

Carney complex (CNC) is a familial neoplasia syndrome associated with growth hormone (GH) excess (GHE). To describe the frequency of GHE in a large cohort of patients with CNC, and to identify genotype-phenotype correlations. Patients with CNC with at least one biochemical evaluation of GH secretion at our center from 1995-2021 (n=140) were included in the study. Diagnosis of GHE was based on levels of insulin-like growth factor-1 (IGF-1), GH suppression during oral glucose tolerance test (OGTT), GH stimulation after thyrotropin (TRH) administration and overnight GH secretion. Fifty patients (35.7%) had GHE and 28 subjects (20%) had symptomatic acromegaly, with median age at diagnosis of 25.3 and 26.1 years respectively. Most of the patients (99.3%) had a PRKAR1A gene defect. There was a higher risk of GHE in patients harboring a variant that led to no expression of the affected allele [Hazard risk (HR): 3.06, 95% Confidence Intervals (CI): 1.2-7.8] and for patients harboring the hotspot variant c.491_492delTG (HR: 2.10, 95%CI: 1.1-4.1). Almost half of patients with CNC had an abnormal finding on pituitary imaging. CNC patients with an abnormal pituitary imaging had higher risk of GHE (HR: 2.94, 95%CI: 1.5-5.8), especially when single or multiple adenoma-like lesions were identified. Management of patients with symptomatic acromegaly involved surgical and medical approaches. Dysregulation of GH secretion is a common finding in CNC. The clinical spectrum of this disorder and its association with genetic and imaging characteristics of the patient make prompt diagnosis and management more successful.

Identifiants

pubmed: 38626285
pii: 7646787
doi: 10.1210/clinem/dgae253
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Published by Oxford University Press on behalf of the Endocrine Society 2024.

Auteurs

Christina Tatsi (C)

Unit on Hypothalamic and Pituitary Disorders, Eunice Kennedy Shriver National Institute of Child Health, and Human Development, National Institutes of Health, Bethesda, Maryland, USA.

Georgia Pitsava (G)

Unit on Hypothalamic and Pituitary Disorders, Eunice Kennedy Shriver National Institute of Child Health, and Human Development, National Institutes of Health, Bethesda, Maryland, USA.

Fabio R Faucz (FR)

Molecular Genomics Core, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.

Meg Keil (M)

Office of the Clinical Director, Eunice Kennedy Shriver National Institute of Child Health, and Human Development (NICHD), National Institutes of Health, Bethesda, Maryland, USA.

Constantine A Stratakis (CA)

Unit on Hypothalamic and Pituitary Disorders, Eunice Kennedy Shriver National Institute of Child Health, and Human Development, National Institutes of Health, Bethesda, Maryland, USA.
Human Genetics & Precision Medicine, IMBB, FORTH, Heraklion, Greece.
Medical Genetics, H. Dunant Hospital, Athens, Greece.
ELPEN Research Institute, Athens, Greece.

Classifications MeSH